niacinamide has been researched along with Wasting Disease in 2 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib-treated patients lost skeletal muscle progressively at 6 months (decrease of 4." | 2.75 | Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. ( Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB; Venner, P, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Toledo, M | 1 |
| Penna, F | 1 |
| Busquets, S | 1 |
| López-Soriano, FJ | 1 |
| Argilés, JM | 1 |
| Antoun, S | 1 |
| Birdsell, L | 1 |
| Sawyer, MB | 1 |
| Venner, P | 1 |
| Escudier, B | 1 |
| Baracos, VE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.[NCT00073307] | Phase 3 | 903 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| A Phase II Double Blind Randomized Trial Comparing Standard Dosing Based on Body Surface Area Versus Dosing Based on Personalized Lean Body Mass in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Receiving First Line Cisplatin Based Chemotherapy[NCT01624051] | Phase 2 | 144 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 542 |
| Placebo | 436 |
Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 542 |
| Placebo | 461 |
PFS determined as the time (days) from the date of randomization at start of study to the actual date of disease progression (PD) (radiological or clinical) or death due to any cause, if death occurred before PD. Outcome measure was assessed approximately every 8 weeks using RECIST v1.0 criteria by independent radiologic review. Radiological PD defined as at least 20% increase in sum of longest diameter (LD) of measured lesions taking as reference smallest sum LD recorded since treatment started or appearance of new lesions. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 167 |
| Placebo | 84 |
Best overall response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 by independent radiologic review. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased) and not evaluated. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Evaluated | |
| Placebo | 0.0 | 0.0 | 55.2 | 30.3 | 14.5 |
| Sorafenib (Nexavar, BAY43-9006) | 0.0 | 2.1 | 77.9 | 8.7 | 11.3 |
"Primary Analysis for FKSI-10 patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FKSI-10 patient responses for each question range from 0=not at all to 4=very much and after reverse coding the range of values for FKSI-10 total score is from 0 to 40; higher score represents better HRQOL." (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.
| Intervention | Scores on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5, Day 1 | Cycles 1-5 (Overall) | |
| Placebo | 27.78 | 27.28 | 26.78 | 26.28 | 27.20 |
| Sorafenib (Nexavar, BAY43-9006) | 27.77 | 27.27 | 26.77 | 26.27 | 27.19 |
"Primary Analysis for FACT-G (using PWB score) patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FACT-G (PWB score) patient responses for each question range from 0=not at all to 4=very much and after reverse coding the total FACT-G (PWB score) range of values is from 0 to 28; higher score represents better HRQOL." (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.
| Intervention | Scores on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5, Day 1 | Cycles 1-5 (Overall) | |
| Placebo | 21.16 | 20.72 | 20.28 | 19.84 | 20.65 |
| Sorafenib (Nexavar, BAY43-9006) | 21.21 | 20.77 | 20.33 | 19.89 | 20.70 |
1 trial available for niacinamide and Wasting Disease
| Article | Year |
|---|---|
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; F | 2010 |
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; F | 2010 |
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; F | 2010 |
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; F | 2010 |
1 other study available for niacinamide and Wasting Disease
| Article | Year |
|---|---|
Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3.
Topics: Animals; Antineoplastic Agents; Cachexia; Carcinoma, Lewis Lung; Colon; Colonic Neoplasms; Lung; Mel | 2014 |